OpenSpecial NoticeFederal
HT9426-27-NOI-049825
Department of Defense · Defense Health Agency (dha)
Due Closes in 42 daysRef. HT9426-27-NOI-049825
At a glance
- What
The Defense Health Agency Contracting Activity (DHACA) on behalf of the WRAIR, CMPN, ISB, intends to negotiate on a sole source basis in accordance with RFO 6.103 with vendor Mitochon Pharmaceuticals, Inc. 970 Cross Lane, Blue Bell, PA…
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (NAICS 541715)
- Who can bid
- Any business — no set-aside listed
- Where
- Blue Bell, PA
- Key dates
- Posted: Nov 18, 2026
- Deadline: Thu, Dec 31, 2026 · 1:00 PM EST (closes in 42 days)
- How to respond
Herbert Keen · herbert.e.keen.civ@health.mil · 3016193439
Submit per the instructions on SAM.gov ↗
- Documents
- None attached here — check SAM.gov
Description
The Defense Health Agency Contracting Activity (DHACA) on behalf of the WRAIR, CMPN, ISB, intends to negotiate on a sole source basis in accordance with RFO 6.103 with vendor Mitochon Pharmaceuticals, Inc. 970 Cross Lane, Blue Bell, PA 19422-1574. The contractor shall supply two (2) Batches of the proprietary prodrug MP201 to ISB for testing Acute Stress Reactions (ASRs). This includes providing quality control documentation and dosage background information. Additionally, the contractor shall provide informational support to the ISB research team by assisting with preparing reports and manuscripts related to MP201. Each batch of synthesized MP201 shall consist of a freshly made lot of prodrug to determine target dosage in the range of approximately 8 - 80 mg/kg body weight. These doses shall be developed in quantities to support oral administration in mice.
Read more ↓Show less ↑
THIS NOI IS NOT A REQUEST FOR COMPETITIVE PROPOSALS, and no solicitation document exists for this requirement. Meaningful submissions received in response to this notice will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government.. Responsible, interested parties may identify their interest by submitting capability statements (using PDF, MS Word, or Excel attachments), in writing, by 2:00 p.m. Eastern Time, 31 December 2026 to Herbert Keen at herbert.e.keen.civ@health.mil and Mr. Lance Nowell at lance.l.nowell.civ@health.mil. Supporting evidence must be furnished in sufficient detail to demonstrate the firms ability to provide the stated capability. Information and materials submitted in response to this request WILL NOT be returned. DO NOT SUBMIT CLASSIFIED MATERIAL. Responses will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses to this notice is solely within the discretion of the Government. If no responses are received, the DHACA will proceed with the sole source contract issued to Mitochon Pharmaceuticals, Inc.
Other notices in this solicitation
All notice detailsShow ↓
- Solicitation number
- HT9426-27-NOI-049825
- Notice type
- Special Notice
- Product/service code (PSC)
- AN14
- Department
- Department of Defense
- Sub-agency
- Defense Health Agency (dha)
- Contracting office
- DEFENSE HEALTH AGENCY
- Office location
- FORT DETRICK, MD, 21702
- Place of performance
- Mitochon Pharmaceuticals, Inc. 970 Cross Lane, Blue Bell, PA 19422-1574., Blue Bell, PA, 19422
- Archive date
- Jan 18, 2027
- Archive type
- autocustom
- Organization type
- OFFICE
- Full agency path
- DEPT OF DEFENSE.DEFENSE HEALTH AGENCY (DHA).DEFENSE HEALTH AGENCY
- SAM.gov notice ID
- f36eb9975e5b4f928396d9d01a0415e5
Industry (NAICS)
Contacts
- Herbert Keen · primaryherbert.e.keen.civ@health.mil(awards)3016193439
Closes in 42 days🔔 Get alerts for bids like this